JP2022538299A5 - - Google Patents
Info
- Publication number
- JP2022538299A5 JP2022538299A5 JP2021577424A JP2021577424A JP2022538299A5 JP 2022538299 A5 JP2022538299 A5 JP 2022538299A5 JP 2021577424 A JP2021577424 A JP 2021577424A JP 2021577424 A JP2021577424 A JP 2021577424A JP 2022538299 A5 JP2022538299 A5 JP 2022538299A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- group
- compound
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025000024A JP2025060984A (ja) | 2019-06-27 | 2025-01-05 | Ｃｎｓ障害を治療するための組成物及び方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962867618P | 2019-06-27 | 2019-06-27 | |
| US62/867,618 | 2019-06-27 | ||
| PCT/US2020/040153 WO2020264509A1 (en) | 2019-06-27 | 2020-06-29 | Compositions and methods for treating cns disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025000024A Division JP2025060984A (ja) | 2019-06-27 | 2025-01-05 | Ｃｎｓ障害を治療するための組成物及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022538299A JP2022538299A (ja) | 2022-09-01 |
| JP2022538299A5 true JP2022538299A5 (https=) | 2023-07-07 |
| JP7787635B2 JP7787635B2 (ja) | 2025-12-17 |
Family
ID=71728947
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021577424A Active JP7787635B2 (ja) | 2019-06-27 | 2020-06-29 | Ｃｎｓ障害を治療するための組成物及び方法 |
| JP2025000024A Pending JP2025060984A (ja) | 2019-06-27 | 2025-01-05 | Ｃｎｓ障害を治療するための組成物及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025000024A Pending JP2025060984A (ja) | 2019-06-27 | 2025-01-05 | Ｃｎｓ障害を治療するための組成物及び方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12552829B2 (https=) |
| EP (1) | EP3990469A1 (https=) |
| JP (2) | JP7787635B2 (https=) |
| KR (1) | KR20220038680A (https=) |
| CN (1) | CN114391019A (https=) |
| AR (1) | AR119305A1 (https=) |
| AU (1) | AU2020302748A1 (https=) |
| BR (1) | BR112021026462A2 (https=) |
| CA (1) | CA3143509A1 (https=) |
| IL (1) | IL289172A (https=) |
| MX (3) | MX2021015942A (https=) |
| TW (1) | TWI896547B (https=) |
| WO (1) | WO2020264509A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2882708A1 (en) | 2012-08-21 | 2014-02-27 | Sage Therapeutics, Inc. | Methods of treating epilepsy or status epilepticus |
| KR102396328B1 (ko) | 2013-04-17 | 2022-05-10 | 세이지 테라퓨틱스, 인크. | 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법 |
| US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| WO2016082789A1 (en) | 2014-11-27 | 2016-06-02 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| EP3504189A1 (en) | 2016-08-23 | 2019-07-03 | Sage Therapeutics, Inc. | A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid |
| MA51046A (fr) | 2017-12-08 | 2021-03-17 | Sage Therapeutics Inc | Dérivés de 21-[4-cyano-pyrazol-1-yl]-19-nor-pregan-3. alpha-ol-20-one deutérés pour le traitement de troubles du snc |
| SG11202112391UA (en) | 2019-05-31 | 2021-12-30 | Sage Therapeutics Inc | Neuroactive steroids and compositions thereof |
| CA3143509A1 (en) | 2019-06-27 | 2020-12-30 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2969M (fr) | 1963-05-22 | 1964-11-30 | Roussel Uclaf | Nouveau médicament notamment pour le traitement des spasmes d'origine coronarienne on viscérale. |
| ES432106A1 (es) | 1973-11-30 | 1976-11-01 | Schering Ag | Procedimiento para la preparacion de d-homo-20-cetopregna- nos. |
| IL48628A0 (en) | 1974-12-23 | 1976-02-29 | Schering Ag | D-homo-20-keto-pregnanes and process for their manufactur |
| GB1570394A (en) | 1976-01-06 | 1980-07-02 | Glaxo Lab Ltd | 11-acyloxy-3-hydroxy steroids |
| US4060295A (en) | 1976-03-15 | 1977-11-29 | Molex Incorporated | Zero insertion force printed circuit board edge connector assembly |
| GB1581234A (en) | 1976-04-05 | 1980-12-10 | Glaxo Operations Ltd | 11a - amino - 3a - hydroxysteroids |
| GB1581235A (en) | 1977-04-04 | 1980-12-10 | Glaxo Operations Ltd | 11a-amino-3a-hydroxy-steroids |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| NZ298567A (en) | 1994-11-23 | 2000-01-28 | Cocensys Inc | Androstane and pregnane derivatives, pharmaceutical compositions and methods of treatment |
| WO1998005337A1 (en) | 1996-08-01 | 1998-02-12 | Cocensys, Inc. | Use of gaba and nmda receptor ligands for the treatment of migraine headache |
| WO2005105822A2 (en) | 2004-04-23 | 2005-11-10 | Euro-Celtique S.A. | 3-alpha-hydroxy 21-n- heteroaryl-pregnane derivatives for modulation of brain excitability and a process for the production thereof |
| CN101585862B (zh) * | 2008-05-20 | 2014-12-17 | 梅克芳股份公司 | 甾族化合物 |
| CA2848212C (en) | 2011-09-08 | 2022-03-29 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| KR102396328B1 (ko) | 2013-04-17 | 2022-05-10 | 세이지 테라퓨틱스, 인크. | 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법 |
| ES2805598T3 (es) | 2014-05-29 | 2021-02-12 | Sage Therapeutics Inc | Esteroides neuroactivos, composiciones y usos de los mismos |
| CN117024501A (zh) * | 2014-10-16 | 2023-11-10 | 萨奇治疗股份有限公司 | 靶向cns障碍的组合物和方法 |
| WO2017049044A1 (en) | 2015-09-16 | 2017-03-23 | Bartolucci Giampiero | Ursodeoxycholic acid and brain disorders |
| KR20240157128A (ko) | 2016-03-08 | 2024-10-31 | 세이지 테라퓨틱스, 인크. | 신경활성 스테로이드, 조성물, 및 그의 용도 |
| WO2018013615A1 (en) * | 2016-07-11 | 2018-01-18 | Sage Therapeutics, Inc. | C7, c12, and c16 substituted neuroactive steroids and their methods of use |
| CA3068462A1 (en) | 2017-06-23 | 2019-12-27 | The Board Of Trustees Of The University Of Illinois | Treatment of neuropsychiatric disorders with neurosteroids and analogues thereof |
| WO2019041078A1 (en) | 2017-08-28 | 2019-03-07 | Zhejiang Jiachi Pharmaceutical Development Ltd. | ASYMMETRIC SYNTHESIS AND USES OF COMPOUNDS IN TREATMENT OF DISEASES |
| WO2019051264A1 (en) * | 2017-09-07 | 2019-03-14 | Sage Therapeutics, Inc. | NEUROACTIVE STEROIDS AND METHODS OF USE |
| BR112020012761A2 (pt) * | 2017-12-22 | 2021-02-17 | Sage Therapeutics, Inc. | composições e métodos para o tratamento de distúrbios do snc |
| WO2019154257A1 (zh) | 2018-02-11 | 2019-08-15 | 江苏豪森药业集团有限公司 | 一种甾族类衍生物调节剂及其制备方法和应用 |
| KR20250174100A (ko) | 2018-12-05 | 2025-12-11 | 세이지 테라퓨틱스, 인크. | 신경활성 스테로이드 및 이의 사용 방법 |
| CN115651054B (zh) | 2019-01-08 | 2024-06-21 | 成都康弘药业集团股份有限公司 | 甾体类化合物、用途及其制备方法 |
| WO2020210117A1 (en) * | 2019-04-08 | 2020-10-15 | Athenen Therapeutics, Inc. | Steroids with altered pharmacokinetic properties and methods of use thereof |
| WO2020210116A1 (en) * | 2019-04-08 | 2020-10-15 | Athenen Therapeutics, Inc. | Steroids with altered pharmacokinetic properties and methods of use thereof |
| SG11202112391UA (en) * | 2019-05-31 | 2021-12-30 | Sage Therapeutics Inc | Neuroactive steroids and compositions thereof |
| JP7754725B2 (ja) | 2019-06-27 | 2025-10-15 | セージ セラピューティクス， インコーポレイテッド | Ｃｎｓ障害を治療するための組成物及び方法 |
| CA3143509A1 (en) * | 2019-06-27 | 2020-12-30 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| CN114729000A (zh) | 2019-06-27 | 2022-07-08 | 萨奇治疗股份有限公司 | 用于治疗cns病症的化合物 |
| WO2022115381A1 (en) * | 2020-11-25 | 2022-06-02 | Sage Therapeutics, Onc. | Compositions and methods for treating cns disorders cross reference to related application |
-
2020
- 2020-06-29 CA CA3143509A patent/CA3143509A1/en active Pending
- 2020-06-29 CN CN202080059463.9A patent/CN114391019A/zh active Pending
- 2020-06-29 BR BR112021026462A patent/BR112021026462A2/pt unknown
- 2020-06-29 KR KR1020227002448A patent/KR20220038680A/ko active Pending
- 2020-06-29 TW TW109121938A patent/TWI896547B/zh active
- 2020-06-29 JP JP2021577424A patent/JP7787635B2/ja active Active
- 2020-06-29 WO PCT/US2020/040153 patent/WO2020264509A1/en not_active Ceased
- 2020-06-29 AU AU2020302748A patent/AU2020302748A1/en active Pending
- 2020-06-29 MX MX2021015942A patent/MX2021015942A/es unknown
- 2020-06-29 EP EP20743476.2A patent/EP3990469A1/en active Pending
- 2020-06-29 AR ARP200101836A patent/AR119305A1/es unknown
- 2020-06-29 US US17/620,226 patent/US12552829B2/en active Active
-
2021
- 2021-12-16 MX MX2024009926A patent/MX2024009926A/es unknown
- 2021-12-16 MX MX2024009925A patent/MX2024009925A/es unknown
- 2021-12-20 IL IL289172A patent/IL289172A/en unknown
-
2025
- 2025-01-05 JP JP2025000024A patent/JP2025060984A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022538299A5 (https=) | ||
| JP2022538301A5 (https=) | ||
| JP2022510683A5 (https=) | ||
| JP2022538300A5 (https=) | ||
| JP2022516469A5 (https=) | ||
| US7402605B2 (en) | 8-azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient | |
| JP4344235B2 (ja) | タキソール増強剤化合物 | |
| JP2024050527A5 (https=) | ||
| JP2022532706A5 (https=) | ||
| JP2021514001A5 (https=) | ||
| RU2020123151A (ru) | Антагонисты tlr7/8 и их применение | |
| JPWO2023042879A5 (https=) | ||
| JP2019512485A5 (https=) | ||
| JP2016534134A5 (https=) | ||
| RU2017145650A (ru) | Ингибиторы тирозинкиназы брутона | |
| JPWO2019013311A5 (https=) | ||
| JP2023518411A5 (https=) | ||
| JP2022504607A5 (https=) | ||
| JP2022525069A5 (https=) | ||
| JP2023504542A5 (https=) | ||
| AU2002238855B2 (en) | N-phenylarylsulfonamide compound, drug containing the compound as active ingredient, intermediate for the compound, and processes for producing the same | |
| JP2022548250A5 (https=) | ||
| RU2016111138A (ru) | Гетероциклические соединения и способы их применения | |
| JP2020111571A5 (https=) | ||
| JP2021535137A5 (https=) |